Friday Pop Quiz 11/28/2025
A previously healthy 55-year-old patient presents with a four-month history of the pictured indurated papules and plaques. History does not reveal prior skin problems. The lesions started on the cheeks and are now affecting the forehead. The sun seems to exacerbate the condition, causing mild burning and pruritus. Patient complains of cheek swelling that worsens in the morning and improves as …
A previously healthy 55-year-old patient presents with a four-month history of the pictured indurated papules and plaques. History does not reveal prior skin problems. The lesions started on the cheeks and are now affecting the forehead. The sun seems to exacerbate the condition, causing mild burning and pruritus. Patient complains of cheek swelling that worsens in the morning and improves as … 
The September edition of the Journal of Drugs in Dermatology (JDD) focuses on aesthetic treatments, exploring the latest advancements and innovative approaches that are reshaping dermatologic care. This month’s Editor's Picks bring together a selection of cutting-edge research, from the use of genomic analysis in melanoma management to AI’s influence on beauty standards.
Explore the latest … 
A study in the August Journal of Drugs in Dermatology addressed the burden of melasma – the populations most prone to melasma and the comorbidities associated with it. According to the study’s authors, a deeper understanding of the associations of race, ethnicity and comorbidities can help dermatologists determine which patients are at risk of developing melasma and as well as potential new pa … 
Metronidazole is a nitroimidazole with antiprotozoal, antibacterial, and anti-inflammatory properties and is available in oral and topical formulations. The diverse mechanisms of action of metronidazole have expanded its utility across various dermatologic conditions. Topical metronidazole is well tolerated and has demonstrated improvements in inflammatory papules and pustules of rosacea. We conti … 
Oxymetazoline is an adrenoreceptor agonist which is FDA-approved for dermatologic conditions including persistent facial erythema in rosacea and blepharoptosis. Functioning primarily as a vasoconstrictor with additional anti-inflammatory properties, oxymetazoline targets the sustained vasodilated state of cutaneous blood vessels in rosacea by inducing vasoconstriction and reducing the persistent f …